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1. Introduction 
Young women have an inferior risk of cardiac events, but this benefit fades after 
menopause, leaving them at risk to develop a cardiovascular disease (CVD) (Stramba-
Badiale, Fox et al. 2006). Endocrine and gynecologic diseases may have impact on this 
pattern. Ever since the classical notice of Stein and Leventhal in 1935 (Stein and Leventhal. 
1935), interest in polycystic ovaries (PCO) and its accompanying syndrome (PCOS) has 
grown from a ‘‘gynecological curiosity to a multisystem endocrinopathy’’ (Homburg 1996). 
Actually, polycystic ovary syndrome (PCOS), is the most common female endocrinopathy in 
up to 10% in reproductive age and appears to be related with an increased cardiovascular 
risk (Talbott, Guzick et al. 1995; Cibula, Cifkova et al. 2000). The syndrome is characterized 
by chronic anovulation and hyperandrogenism (Franks 1995; Scarpitta and Sinagra 2000). 
Cardiovascular disease and type 2 diabetes are two potential major long-term sequelae of 
this condition that is worth of examination. 
Even though the first description occurred almost 70 years ago, there has not been 
agreement about its definition. At a recent collective European Society of Human 
Reproduction and Embryology/American Society for Reproductive Medicine 
(ESHRE/ASRM) consensus meeting, a refined definition of PCOS was agreed: particularly, 
the presence of two out of the following three criteria: 
i. oligo- and/or anovulation 
ii. hyperandrogenism (clinical and/or biochemical) 
iii. polycystic ovaries, with the exclusion of other etiologies (2004). 
It is widely accepted that polycystic ovary syndrome (PCOS) is correlated with an increased 
risk of cardiovascular disease. Dyslipidaemia (Legro, Kunselman et al. 2001; Pirwany, 
Fleming et al. 2001), hypertension (Dahlgren, Janson et al. 1992; Luque-Ramirez, Alvarez-
Blasco et al. 2007) and diabetes (Ehrmann, Barnes et al. 1999; Legro, Kunselman et al. 1999) 
are appeared to be more common in women with PCOS. Obesity, especially central obesity, 
is a pivotal factor for predicting the long-term risk of cardiovascular disease (Franks, Kiddy 
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et al. 1991; Luque-Ramirez, Alvarez-Blasco et al. 2007). There is substantial convergence 
among these features found in PCOS and the metabolic syndrome, and it is potential that 
these are interrelated conditions. Alterations in clotting (Manneras-Holm, Baghaei et al. 
2011) and blood vessel function (Paradisi, Steinberg et al. 2001) might describe why 
cardiovascular disease is a long-term risk in women with PCOS. 
However metabolic abnormalities aforementioned and obesity were not recognized until 
reduced sensitivity to insulin and compensatory hyperinsulinemia were demonstrated in 
PCOS patients. The metabolic profile well known in women with PCOS, is equivalent to the 
insulin resistance syndrome, a clustering within an individual with hyperinsulinemia, mild 
glucose intolerance, dyslipidemia, and hypertension. The insulin resistance syndrome (or 
syndrome X) has been recognized as a risk factor for developing type 2 diabetes and CVD 
(Legro, Kunselman et al. 1999; Korhonen, Hippelainen et al. 2001). 
There is also a strong association between hyperandrogenemia and insulin resistance in 
PCOS (Bremer and Miller 2008). This may mainly consider the stimulatory effect of 
hyperinsulinemia on ovarian androgen production, although hyperandrogenemia may 
finally contribute to insulin resistance (Baptiste, Battista et al. 2010). This may also underlie 
the association between hyperandrogenemia and impaired vascular function and reported 
in some studies involving PCOS subjects (Wu and von Eckardstein 2003). Nevertheless, 
even though insulin resistance per se has been associated with endothelial dysfunction and 
increased cardiovascular risk, there is no stable proof that hyperandrogenemia is a risk 
factor for cardiovascular disease in women (Gorgels, v d Graaf et al. 1997). 
Notwithstanding the fact that PCOS is increasingly recognized as being associated with a 
cluster of cardiovascular risk factors, there is no final evidence for increased cardiovascular 
events in PCOS. Nor is there, evidently, data show that PCOS alone imparts increased risk 
independent of associated risk factors. This article intends to review the spectrum of 
cardiovascular risk factors, the cardiovascular epidemiology and especially the most recent 
studies of subclinical cardiovascular disease in PCOS, investigating cardiovascular structure 
and function. Although, these latter sets of studies have, in particular, further elucidated the 
causal links between PCOS and cardiovascular disease. 
2. Cardiovascular risk factors in PCOS 
2.1 Biochemical 
2.1.1 Hyperinsulinemia and insulin resistance 
Insulin resistance, described as a reduced glucose response to a given amount of insulin, is a 
typical metabolic disturbance related with PCOS. Resistance to the activity of insulin in 
target tissues is a main pathogenic factor in metabolic syndrome and type 2 diabetes. 
Association of PCOS with insulin resistance was known nearly three decades ago (Burghen, 
Givens et al. 1980). Hyperinsulinemic euglycemic clamp measurements have shown that 
insulin-mediated glucose uptake have decreased by 35-40% in both lean and obese women 
with PCOS, similar to the degree of insulin resistance seen in patients with type 2 diabetes 
(Dunaif, Segal et al. 1989). Insulin resistance causes compensatory hyperinsulinemia, which 
is related to many of the phenotypic features of PCOS (menstrual disturbances, evolvement 
of ovarian cysts, hirsutism and other associated disorders) through multiple mechanisms, 
involving ovarian steroidogenesis, gonadotrophin secretion, and sex hormone binding 
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globulin production (Ehrmann 2005). Insulin can enhance ovarian steroidogenesis and 
enhance directly, independently and/or augment LH-mediated androgen production 
(Barbieri, Makris et al. 1984; Poretsky, Cataldo et al. 1999; Bremer and Miller 2008). Hence, 
hyperinsulinemia and hyperandrogenemia are two essential characteristics of PCOS. Their 
cause and effect relationship is still debated (Dunaif 1997; Poretsky, Cataldo et al. 1999; Legro, 
Gnatuk et al. 2005; Bremer and Miller 2008). However, several evidences suggest that 
hyperinsulinemia may be the principal cause leading to the ovarian hyperandrogenemia. 
Insulin level reduction pharmacologically, has been ameliorating hyperinsulinemia as well as 
hyperandrogenemia and restore ovulation in the women with PCOS. Even though, a decrease 
in androgen levels by bilateral oophorectomy, administration of GnRH agonist (Bremer and 
Miller 2008), or antiandrogenic combinations (Dunaif 1997) had no impact on IR or 
hyperinsulinemia in the PCOS women, which would have been expected if 
hyperandrogenemia was the factor of hyperinsulinemia. Besides, the peripheral insulin 
resistance in PCOS was related to defective pancreatic ß-cell function (Ehrmann, Sturis et al. 
1995). Additionally, insulin resistance increases the risk for evolvement of glucose intolerance, 
type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia and cardiovascular abnormalities 
in these patients (Maitra, Pingle et al. 2001; Legro, Gnatuk et al. 2005). 
PCOS patients have a higher incidence of insulin resistance and hyperinsulinemia than age-
matched controls in both obese and nonobese patients. Nonetheless, obese women with 
PCOS have significantly decreased insulin sensitivity compared with nonobese women who 
have PCOS. Insulin resistance has been known to lead to the progression of type 2 diabetes 
mellitus. PCOS patients have progress to impaired glucose tolerance in 30% to 40% of the 
cases, and as many as 10% of them develop type 2 diabetes mellitus by the age of 40 
(Clayton, Ogden et al. 1992; Guzick 2004; Tsilchorozidou, Overton et al. 2004). Strong 
association between insulin resistance and hyperandrogemia has been shown by several 
studies. This association was first reported by Achard and Thiers in 1921 in a bearded 
woman who was also a diabetic (Guzick 2004). Androgen production is magnified 
synergistically with LH and insulin action in the ovarian theca cells. In addition insulin 
decreases hepatic synthesis and release of sex hormone-binding globulin, the hormone that 
binds testosterone in the blood flow, hence increasing the amount of free testosterone that is 
biologically attainable (Tsilchorozidou, Overton et al. 2004). Free testosterone levels 
typically have been increased in hyperinsulinemic PCOS patients. Although the total 
testosterone concentration may be at the upper range of normal or only moderately elevated 
(Tsilchorozidou, Overton et al. 2004).The exact cellular and molecular mechanisms of insulin 
resistance in PCOS remain elusive in spite of the crucial role of insulin resistance in the 
pathogenesis of this syndrome. Together intrinsic and acquired defects in insulin signaling, 
have been known as mediators of insulin resistance in women with PCOS.  
In PCOS the “central paradox” is characterized by responsive ovaries to insulin effect to 
produce androgens in spite of systemic insulin resistant state; nonetheless, classical target 
organs of insulin as well as ovary remains resistant to its metabolic activity. Distinct insulin 
target tissues and ovary have comprised optimal number and affinity of insulin receptors, 
and as well as no structural and mutational abnormalities could be detected in the PCOS 
women (Dunaif 1997; Ciaraldi, Morales et al. 1998; Book and Dunaif 1999; Poretsky, Cataldo 
et al. 1999). Therefore, a post-receptor binding defect in the insulin signaling pathway 
appears to play a consequential function in the etiology of selective IR. Notwithstanding the 
fact that several in vitro and in vivo researches have been carried out in various tissues to 
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illuminate the possible mechanism of IR and hyperandrogenemia (ovarian cells) (Ovarian 
cells, adipocytes, fibroblasts, myocytes) (Dunaif 1997; Poretsky, Cataldo et al. 1999; Pessin 
and Saltiel 2000; Nelson-Degrave, Wickenheisser et al. 2005; Diamanti-Kandarakis and 
Papavassiliou 2006) in PCOS patients, however the data has not been yet conclusive. 
Pancreatic ǃ-cell dysfunction has been described in women with PCOS, whereby there is 
augmented basal secretion of insulin in spite of an insufficient postprandial response 
(Ehrmann, Sturis et al. 1995). This imperfection remains even after weight loss, despite an 
amelioration in glucose tolerance (Holte, Bergh et al. 1995). Insulin performs its effects via 
insulin receptor to begin a cascade of post-receptor events within the target cell. 
Phosphorylation stimulates insulin receptor substrates (IRS1-4) to promote glucose uptake 
through the transmembrane glucose transporter (GLUT4) and additionally intracellular 
protein synthesis. Tyrosine phosphorylation increments the tyrosine kinase activity of the 
insulin receptor, while serine phosphorylation inhibits it, and it appears that at least 50% of 
PCOS patients have excessive serine phosphorylation and inhibition of normal signaling 
(Tsilchorozidou, Overton et al. 2004). This influences merely glucose homeostasis and not 
the other pleiotropic activity of insulin, so that cell growth and protein synthesis continue. 
In addition, serine phosphorylation boosts activity of P450c17 in both the ovary and adrenal 
gland, hence promoting androgen synthesis, and this may be a reason for both insulin 
resistance and hyperandrogenism in some PCOS patients (Zhang, Rodriguez et al. 1995). 
The source of hyperinsulinemia in patients with PCOS also remains unknown. The post 
receptor insulin signaling pathway and/or defective insulin secretion may be associated 
with an intrinsic abnormality (Holte, Bergh et al. 1995; Dunaif 1997). Probably, the metabolic 
abnormalities in PCOS begin very early in life, during the prenatal or prepubertal period, 
and an early exposure to androgens during growth may affect the body fat distribution and 
insulin action (Abbott, Dumesic et al. 2002; Eisner, Barnett et al. 2002). These observations 
have shown convincing proof that PCOS patients have insulin resistance and/or 
hyperinsulinemia, especially when they are anovulatory and obese with central fat 
distribution. Given that insulin resistance is an independent risk factor for metabolic 
abnormalities, the presence of insulin resistance in PCOS women implies the future 
possibility of cardiovascular disease and type 2 diabetes. Moreover, applying a 
cardiovascular risk score, insulin resistance in PCOS was established to be an important 
independent determining factor of cardiovascular risk in women with PCOS (Mather, Kwan 
et al. 2000). 
The 2003 Rotterdam Consensus Conference (at least two of three features: 
oligo/anovulation, clinical and/or biochemical hyperandrogenism, polycystic ovaries) 
(2004) revised the 1990 US National Institutes of Health (NIH) definition of PCOS 
(hyperandrogenism and/or hyperandrogenemia plus oligo-ovulation, with the exclusion of 
other causes) (Zawadzki and Dunaif 1992), started a great debate. The majority of the 
studies investigating the metabolic associations of PCOS have used the 1990 NIH definition. 
Existing proofs support an increased risk of metabolic dysfunction in patients with clinical 
and/or biochemical hyperandrogenism and oligoovulation, and also in women with 
hyperandrogenism and normoovulation with polycystic ovaries (Azziz, Carmina et al. 
2006). Women with or without oligoovulation with polycystic ovaries have nil or very subtle 
metabolic characteristics that makes it difficult for their involvement as a syndrome (Azziz, 
Carmina et al. 2006; Barber, Wass et al. 2007). 
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Dyslipidemia is one of the most verified independent risk factors for the development of 
atherosclerotic cardiovascular disease, especially elevated low-density lipoprotein (LDL) 
and triglyceride (TG) levels. The most common metabolic abnormality in PCOS may be 
dyslipidemia, with a prevalence of up to 70% according to National Cholesterol Education 
Program criteria (Dunaif, Segal et al. 1989; Talbott, Clerici et al. 1998; Legro, Kunselman et 
al. 1999).  
Insulin resistance, and its common, but not constant companion, compensatory 
hyperinsulinemia, have been linked with other different patterns of dyslipidemia. These 
include low levels of high-density lipoprotein(HDL)-cholesterol (HDL-C), increased values 
of triglycerides and total and low-density lipoprotein (LDL)-cholesterol (LDL-C), as well as 
varied LDL quality (Talbott, Clerici et al. 1998; Legro, Kunselman et al. 2001; Pirwany, 
Fleming et al. 2001; Essah, Nestler et al. 2008; Valkenburg, Steegers-Theunissen et al. 2008). 
However, lower HDL levels, higher low-density lipoprotein (LDL)/HDL ratios and higher 
triglyceride levels are seen most often in both lean and obese women with PCOS (Wild, 
Painter et al. 1985). This lipid pattern is similar to that found in T2DM. And it is mostly the 
result of IR that impairs the capability of insulin to suppress lipolysis, thereby expanding 
mobilization of free fatty acids from adipose stores. As a result, raised hepatic delivery of 
free fatty acids impairs insulin inhibition of hepatic very low-density lipoprotein 1 synthesis, 
causing altered catabolism of very low-density lipoprotein (Brunzell and Ayyobi 2003). 
Excessive adipose tissue increase insulin resistance, and this pattern is more common in 
obese patients with PCOS. These different patterns may be linked to the accompanying 
effects of IR and hyperandrogenism that merge with environmental (diet, physical exercise) 
and genetic factors (Dunaif 1997). 
LDL subclasses are consequential predictors of CVD (Gardner, Fortmann et al. 1996). LDL 
particles are diverse in magnitude, density, and structure. CAD has been associated with 
small dense LDL particles and increased relative risk of CAD, that ranges from 3- to 7-fold 
(Austin, Breslow et al. 1988). Numerous studies have revealed a high prevalence of small 
LDL size in PCOS patients (Wild, Pierpoint et al. 2000; Dejager, Pichard et al. 2001). The 
differences in lipid profile are sharper at earlier ages and minor divergence is notable 
beyond the age of 40 years among to PCOS and control women, suggesting an incresaed risk 
for atherosclerosis at an earlier age (Talbott, Guzick et al. 1995; Talbott, Clerici et al. 1998). 
Existance of hormonal discordance may cause an earlier occurrence of atherosclerosis. 
Obesity and intraabdominal fat distribution in PCOS patients or may reflect the LDL-C 
increment with age among controls.  
Recently, several studies have shown that similar changes of plasma lipids, distinct 
alterations of Lp and apoB substantially increase the cardiovascular risk (2002; Wierzbicki 
2008). ApoB is the principal constitutional component of LDL and a true indicator of the 
number of particles promoting arteriosclerosis (2002). Some studies found no differences in 
apoB levels between women with PCOS and the controls (Valkenburg, Steegers-Theunissen 
et al. 2008). However, the others have shown significant increments in PCOS patients than 
the controls (Demirel, Bideci et al. 2007). Almost certainly, genetic and environmental 
influences may cause different lipid patterns. Based on these present data the determination 
of apoB levels is not advisable in women with PCOS. 
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Lipoprotein(a) is a miscellaneous class of lipoproteins constructed of an apo(a) molecule 
connected to an apoB-100 and a lipid. Lp(a) levels are determined genetically, and its 
metabolic characteristics are different from LDL. The concentration an Lp(a) is remaining 
stable during the life of a subject (Scanu 1992). Elevated Lp(a) concentrations represent an 
independent risk factor for cardiovascular events, associated to a raised risk of myocardium 
infarction, stroke and coronary heart disease (Sandkamp, Funke et al. 1990; Nagayama, 
Shinohara et al. 1994). Many studies and metaanalysis suggest that Lp(a) levels are 
increased in women with PCOS (Rizzo, Berneis et al. 2009; Toulis, Goulis et al. 2011). 
Lipid disorders in PCOS appear to be connected to hyperinsulinemia (Mather, Kwan et al. 
2000) and central obesity (Pirwany, Fleming et al. 2001). Some of the researchers suggested 
that androgen levels were associated with triglyceride levels, and lipids did not have any 
association (Legro, Kunselman et al. 2001). Nevertheless, others found no association 
between androgen levels and dyslipidemia (Pirwany, Fleming et al. 2001). 
The current data suggest that distinct lipid profiles may be present in women with PCOS. 
Furthermore, distinctions among diverse racial and geographical characteristics cannot be 
entirely explained with body weight variations solely (Essah, Nestler et al. 2008; 
Valkenburg, Steegers-Theunissen et al. 2008). These distinctions may depend on the 
combination of genetic, environmental, and hormonal influences. In support of this issue, 
nonobese women with PCOS also can have raised levels of lipoprotein (a), a steady, 
genetically and racially determined, lipid-rich, LDL-like lipoprotein that is metabolically 
different from LDL-C (Scanu 1992; Rizzo, Berneis et al. 2009). 
2.1.3 Hyperandrogenism 
Hyperandrogenism is a dominant characteristic of PCOS with rises of ovarian androgens, 
testosterone, and androstenedione. Sex hormone binding globulin (SHBG) is usually low in 
PCOS, principally due to obesity, leading to higher free testosterone levels (Carmina 2002). 
Hyperandrogenism in PCOS patients, is an indefinite diagnosis of “androgen excess” that 
does not virilize. However, goes beyond the normal limits. Some depend on the clinical 
presentation of peripheral androgen excess in women, involving midline hirsutism, acne, 
and androgenic alopecia to make the diagnosis of hyperandrogenism as part of the PCOS 
phenotype (Hatch, Rosenfield et al. 1981; Lookingbill, Demers et al. 1991). Hirsutism is quite 
more common than the PCOS in the populations. Biochemical criteria, in contrast to clinical 
criteria, are more often used to report hyperandrogenism (Azziz, Ehrmann et al. 2001). 
Generally, it is concluded with serum tests to document increase in circulating androgen 
levels. In many multicenter clinical trials of women with PCOS, testosterone and/or some 
measurements of bioavailable testosterone has been frequently used to determine 
hyperandrogenism (Hines, Moran et al. 2001). 
The gender distinction in vulnerability to cardiovascular disorder has been referred to the 
difference in sex steroids with oestrogen being seen as cardioprotective and androgens as a 
potential for exacerbating cardiovascular risk factors (Wu and von Eckardstein 2003). 
Clinical signs of hyperandrogenism, hirsutism and acne have been recognized as common 
characteristics of women suffering catheterization for coronary artery disease and were 
related with more serious disease (Wild, Grubb et al. 1990). There is little proof of an 
association among androgenic alopecia and raised cardiovascular risk in men, and there is 
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even less in women (Rebora 2001). Iatrogenic hyperandrogenism in female-to-male 
transsexuals does not cause increased cardiovascular mortality (van Kesteren, Asscheman et 
al. 1997). Nevertheless, in an experimental model, testosterone management in female 
primates was related with raised premature atherogenesis, independent of lipid property 
(Adams, Williams et al. 1995). Equivalent trials in animal models of PCOS have not been 
reported to date. 
The CVD is very low in premenopausal women and there was no evidence about correlation 
with increased androgens in circulation or urinary excretion with subsequently developed 
CVD (Gorgels, v d Graaf et al. 1997). Furthermore, prospective researches of 
postmenopausal populations, circulating androgen levels did not correlate with 
cardiovascular events (Price, Lee et al. 1997). The few studies that examined the correlation 
between endogenous androgens and the evolvement of cardiovascular disorder have not 
shown that androgen level performs a significant role in women with PCOS (Barrett-Connor 
and Goodman-Gruen 1995). The carotid intima-medial thickness (CIMT) has been shown to 
be inversely correlated with endogenous dehydroepiandrosterone sulphate (DHEAS) and 
testosterone in premenopausal and postmenopausal women (Bernini, Sgro et al. 1999). 
It looks likely that in spite of the accepted consistent gender disproportion in the prevalence 
of cardiovascular disease, nonhormonal, genetic and environmental circumstances may play 
a greater role than that of androgens. In summary, the evidence for a association between 
hyperandrogenism per se and CVD in women is faint. 
2.1.4 Novel risk factors 
Recent cardiovascular studies have identified new biochemical markers for early 
atherosclerosis, and many of these have been found to be elevated in women with PCOS. 
Preliminary investigations suggest that serum biomarkers of cardiovascular disease, such as C-
reactive protein (Kelly, Lyall et al. 2001; Mohlig, Spranger et al. 2004), adiponectin (Panidis, 
Kourtis et al. 2003; Spranger, Mohlig et al. 2004), plasminogen activator-1 (Sampson, Kong et 
al. 1996), endothelin-1 (Diamanti-Kandarakis, Spina et al. 2001), Von Willebrand factor 
(Dahlgren, Janson et al. 1994), homocysteine (Loverro, Lorusso et al. 2002) and markers of 
oxidative stress (Sabuncu, Vural et al. 2001) were abnormal in women with PCOS. 
Whilst hyperhomocysteinemia is a risk factor for cardiovascular diseases, it has been 
assumed that homocysteine levels are higher in women with PCOS than controls. 
Homocysteine is an amino acid created by the transformation of methionine to cysteine. 
Homocysteine is metabolized by one of two mechanisms: trans-sulfuration and 
remethylation. This procedure needs vitamin B as a cofactor (Dahlgren, Janson et al. 1992; 
Talbott, Guzick et al. 1995; Wild, Pierpoint et al. 2000). 
Potential pathophysiologic mechanisms of the impact of homocysteine comprise intensified 
peroxidation injury, proliferation of the smooth vessel, initiative of monocytic chemotaxis, 
enhanced cytotoxicity and inflammation, promotion of clotting, inhibition of anticoagulation, 
through effects on endothelial cells, and activation of platelet aggregation (Fermo, Vigano' 
D'Angelo et al. 1995; Mayer, Jacobsen et al. 1996; D'Angelo and Selhub 1997). 
Numerous epidemiological reports have established hyperhomocysteinemia as an 
independent risk factor for cardiovascular disease, cerebrovascular disease, recurrent 
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venous thromboembolism. It may arise from genetic defects in the enzymes within 
homocysteine pathways such as a methylene tetrahydrofolate reductase (MTHFR), 
imperfections in vitamin cofactors, or other causes, which contain drugs, such as fibrates 
and nicotinic acid and several chronic medical conditions (D'Angelo, Coppola et al. 2000; 
Orio, Palomba et al. 2003; Dierkes, Westphal et al. 2004; Baccarelli, Zanobetti et al. 2007). 
Many studies have evaluated homocysteine levels in women with PCOS. Most have 
revealed that women with PCOS have increased homocysteine levels when compared with 
controls (de la Calle, Gallardo et al. 2007; Atamer, Demir et al. 2008; Yilmaz, Pektas et al. 
2008; Oktem, Ozcimen et al. 2009). 
The role of inflammation in the evolvement of atherosclerosis has been well clarified. 
Epidemiological researches to have displayed that markers of inflammation, such as C-
reactive protein (CRP) and white cell count, are independent predictors of cardiovascular 
disease odds. Several studies have been displayed elevated levels of high sensitivity CRP 
(Kelly, Lyall et al. 2001; Boulman, Levy et al. 2004), but not all (Mohlig, Spranger et al. 2004), 
in women with PCOS, independent of BMI. Recently, a higher white cell count was found to 
be correlated with a degree of insulin resistance in women with PCOS independent of BMI 
(Orio, Palomba et al. 2005). Predictors of vascular endothelial activation and damage, and 
oxidative stress has also been associated to a raised incidence of cardiovascular hazard, and 
peculiarities of these have been reported in women with PCOS. This issue is controversial if 
these correlations are independent of co-existent causes such as age, obesity, insulin 
resistance, blood pressure, serum glucose and lipid levels. 
The circulating levels of tumour necrosis factor? ǂ (TNF ǂ), interleukin (IL)-6, as well as 
white blood count (WBC) and neutrophil count have been found to be elevated in PCOS 
patients compared with age- and /body mass index- (BMI-) matched controls (Alexander 
1994; Kelly, Lyall et al. 2001; Amato, Conte et al. 2003). However, it has been revealed that 
obesity, and not PCOS status per se, was a major determinant of the circulating 
inflammatory markers TNF ǂ, soluble type 2 TNF receptor, IL-6, and hs-CRP (Escobar-
Morreale, Villuendas et al. 2003; Mohlig, Spranger et al. 2004). Increment in both low-grade 
chronic inflammation and insulin resistance in women with PCOS is related with raised 
central fat excess rather than PCOS status (Puder, Varga et al. 2005). Furthermore, TNF ǂ is 
over expressed in adipose tissue and induces insulin resistance throughout acute and 
chronic effects on insulin-sensitive tissues (Hotamisligil, Shargill et al. 1993). The origin of 
redundant TNF ǂ in PCOS is likely to be adipose tissue in the obese but remain obscure in 
lean women with PCOS. Nevertheless, increased visceral obesity could be a origin of 
redundant TNF ǂ in lean women with PCOS. Other proinflammatory cytokine is IL-18, 
which was showed to be raised in PCOS patients (Stephens, Butts et al. 1992). IL-18 causes 
the production of TNF ǂ which promotes the synthesis of IL-6, which is also thought about a 
strong risk marker for cardiovascular disease (Blankenberg, Tiret et al. 2002). Collectively, 
the above findings reveal that low-grade chronic inflammation could be a novel mechanism 
contributing to increased risk of coronary heart disease in PCOS. 
Adiponectin, leptin and resistin, are bioactive peptides that are known as adipocyokines 
secreted by adipocytes, can affect insulin sensitivity and energy balance. Whether or not they 
have a function in the pathogenesis of PCOS is mysterious. Still the peculiarities in the plasma 
concentrations of adipocytokines independent of obesity and insulin resistance in PCOS have 
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not been consistently demonstrated (Panidis, Kourtis et al. 2003; Spranger, Mohlig et al. 2004). 
The low plasma adiponectin levels have been related with an increased risk of the 
development of type 2 diabetes (Lindsay, Funahashi et al. 2002). Low adiponectin levels have 
also been connected with endothelial dysfunction (Tan, Xu et al. 2004), inflammation (Ouchi, 
Kihara et al. 2003) and coronary artery disease (Kumada, Kihara et al. 2003) 
2.2 Clinical factors 
2.2.1 Obesity 
Obesity is a well defined independent risk factor for the development of type 2 diabetes and 
cardiovascular disorder. The western lifestyle is a major cause that increased the obesity 
prevalence (Kuczmarski, Flegal et al. 1994). The hyperinsulinemia appears to be the 
principal metabolic characteristic in normoglycemic normotensive obese subjects, while 
insulin resistance is not as extensive as formerly thought (Ferrannini, Natali et al. 1997). 
Most momentously, cardiovascular morbidity and mortality are raised in obese women 
independently of other hazardous influences (Manson, Colditz et al. 1990). 
The PCOS patients are usually more obese than age matched controls, and have a rise of both 
BMI and waist/hip ratio (Talbott, Guzick et al. 1995). The appearance of obesity in women 
with PCOS diverges according to geographic location and the obese phenotype being 
remarkably common in the United States of America (Knochenhauer, Key et al. 1998). The UK 
researches showed the prevalence of obesity in PCO women was 35–38% (Kiddy, Sharp et al. 
1990; Balen, Conway et al. 1995). The prevalance of PCOS was 10–38% in Mediterranean 
countries (Diamanti-Kandarakis, Kouli et al. 1999; Asuncion, Calvo et al. 2000) and Norman et 
al. found a prevalance as high as 63% in Australia (Norman, Masters et al. 1995). 
Obesity is related with the insulin resistance, hypertension, dyslipidemia, subclinical 
inflammation and increased platelet activation, which are risk factors for atherosclerosis 
(Despres, Moorjani et al. 1990; Davi, Guagnano et al. 2002; Dalton, Cameron et al. 2003). A 
central obesity, which is demonstrated with an elevated waist/hip ratio, is an important and 
independent cardiovascular risk factor (Norman, Masters et al. 2001). The correlation 
between central obesity and cardiovascular disease in PCOS may be relatively linked to low 
plasma adiponectin levels, even though this postulate has not yet been seriously evaluated 
(Nishizawa, Shimomura et al. 2002).  
2.2.2 Hypertension 
Whether the prevalence of hypertension is increased in women with PCOS is obscure. 
Relevant researches to have utilized varying definitions of PCOS, and a wide diversity of 
techniques to evaluate blood pressure. Furthermore, studies, including those utilizing 24-h 
ambulatory blood pressure monitoring procedures, have stated inconsistent consequences 
(Dahlgren, Janson et al. 1992; Mather, Kwan et al. 2000; Wild, Pierpoint et al. 2000). Obese 
PCOS patients were found to have raised systolic but not diastolic BP compared to weight 
matched control women, although there was no divergence in blood pressure degrees between 
the non-obese group (Legro, Kunselman et al. 2001). Women with oligomenorrhea and 
hirsutism had increased levels of systolic and diastolic blood pressures compared to control 
women (Taponen, Martikainen et al. 2004). Additionally, some research indicated that an 
increased risk of having prehypertension (SBP 120 to 139 mm Hg or DBP 80 to 89 mmg Hg) in 
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women with PCOS (Lo, Feigenbaum et al. 2006), a condition related with a two-times an 
increased risk of death from a cardiovascular disease (Masi, Feigenbaum et al. 1995). 
However, existing data need to be assessed with caution, since small differences in blood 
pressure could have a great effect on the population cardiovascular risk (Rose 1981). The 
absence of momentous association with hypertension is surprising while considering the 
close link between PCOS and the metabolic syndrome. Pertinent studies have, however, 
utilized variable definitions of PCOS and employed a wide variety of techniques to assess 
blood pressure. 
2.2.3 Metabolic syndrome 
Metabolic syndrome, or the insulin resistance syndrome which has been known as a 
constellation of endocrine and biochemical markers that places affected individuals at 
important cardiovascular risk. The metabolic syndrome is described by the presence of three 
out of the five following criteria: fasting serum glucose of 100 mg/dL or greater, blood 
pressure higher than 130/85 mmHg, fasting triglyceride level greater than 150 mg/dL; 
serum high density lipoprotein cholesterol less than 50 mg/dL in females and a woman’s 
waist circumference equal to or greater than 35 inches (88 cm) (2002). 
Individuals with the metabolic syndrome have a raised likelihood of having CVD and 
increased all-cause mortality, nevertheless, in the absence of diabetes or cardiovascular 
disease at baseline (Korytkowski, Mokan et al. 1995). PCOS patients have been found to 
have an increased incidence of the metabolic syndrome (Dahlgren, Landin et al. 1998; 
Baillargeon, Jakubowicz et al. 2004). The prevalence has been stated to be as high as 43% in 
these patients, which is twofold more than the age-adjusted prevalence rate of 24% 
nationally, displayed in the NHANES III survey data analysis (Morin-Papunen, Vauhkonen 
et al. 2000). Dokras et al. revealed the age- and BMI-adjusted prevalence of the metabolic 
syndrome to be 47% in women with PCOS compare to 4.3% in controls, which renders to an 
eleven-fold increased risk (Elter, Imir et al. 2002). 
A waist circumference >88 cm (35 in) or >85 cm defined a central obesity, as proposed by 
the International Diabetes Foundation, appears to be the most common element of the 
metabolic syndrome in PCOS. Unexpectedly, Dokras et al. also displayed a 23% 
prevalence of the metabolic syndrome in those women with PCOS under 30 years of age, 
compared to 0% for their counterparts without PCOS and 6.7% prevalence among the 
same demografic values in women in the NHANES study (Elter, Imir et al. 2002; Shroff, 
Kerchner et al. 2007). Consequently, these researchers suggested that all women with 
PCOS be screened for the metabolic syndrome. Other experts related to this area also 
agreed with this suggestion. 
Furthermore, the important issue is that the usefulness of the metabolic syndrome as a 
predictor of cardiovascular disease and type 2 diabetes was recently elucidated when 
compared with established alternative, more specific risk prediction models. The Diabetes 
Predicting Model and the Framingham cardiovascular risk score estimate the future risk of 
developing type 2 diabetes and cardiovascular disease respectively. They take into 
consideration several risk factors such as ethnicity, age, gender, fasting blood glucose, blood 
pressure, lipids, smoking status and family history. When compared with the metabolic 
syndrome in a population-based cohort study these specific prediction models were found 
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to have raised the sensitivity and specificity in predicting diabetes and cardiovascular 
disease respectively (Stern, Williams et al. 2004). 
2.2.4 Mood disturbances and reduced quality of life 
Accumulating data indicated that mood disturbances, principally severe depression were 
independent risk factors for CVD (Ounpuu, Negassa et al. 2001) and prevalent in PCOS 
(Jones, Hall et al. 2008; Bishop, Basch et al. 2009). Various studies displayed increased 
prevalence of depression and anxiety in women with PCOS. These mood alterations and 
impaired quality of life cause tiredness, sleep disturbances, phobia, appetite changes, and 
binge eating (Hollinrake, Abreu et al. 2007; Bishop, Basch et al. 2009; Jedel, Waern et al. 
2010). Consequenctly, depressed women with PCOS have higher BMI and greater IR as 
CVD risk factors than nondepressed women with PCOS without discrepancies in androgen 
status(Hollinrake, Abreu et al. 2007), whereas weight loss by an energy-restricted diet 
ameliorates their depression and quality of life (Thomson, Buckley et al. 2010). It remains to 
be resolved how mood disturbances as CVD risk factors are associated with shifted stress 
responsiveness in PCOS patients, as demonstrated by excessive ACTH and cortisol stress 
responses, disabled IL-6 reply following stres (Benson, Arck et al. 2009), and raised 
sympathetic nerve activity (Sverrisdottir, Mogren et al. 2008). 
2.2.5 Obstructive sleep apnea 
Reports in recent years have revealed on another comorbidity connected with PCOS, 
obstructive sleep apnea (OSA). OSA has significant clinical consequences, involving raised 
daytime sleepiness, decreased quality of life, and lessened cognitive performance. Serious 
cardiovascular effects have also been shown to consequences from OSA, comprising 
hypertension (Brooks, Horner et al. 1997; Lavie, Herer et al. 2000),stroke (Dyken, Somers et 
al. 1996), and myocardial infarction (Hung, Whitford et al. 1990). Fogel et al. was shown that 
obese women with PCOS had substantially raised Apnea- Hypopnea Index (AHI) when 
compared to age- and weight-matched controls. Moreover, this research demonstrated that 
PCOS patients were also nine times as more likely to suffer from OSA when compared to 
the control group (Fogel, Malhotra et al. 2001). Another study performed by Vgontzas et al. 
displayed sleep-disturbed breathing prevalence 30 times more in PCOS patients than the 
control group (Vgontzas, Legro et al. 2001). 
The high prevalence of OSA has been regard to be a role of both increased levels of 
testosterone as well as the obesity that prevalently accompanies PCOS. Nevertheless, it 
looks that the high commonness of OSA in PCOS cannot be completely explained for based 
on these two causes solely (Nitsche and Ehrmann 2010). Insulin resistance was found to be a 
sharper predictor of sleep disordered breathing than was age, circulating testosterone 
concentrations and BMI (Vgontzas, Legro et al. 2001). It also revealed that women with 
PCOS taking oral contraceptives were reduced probability to have sleep disordered 
breathing, uniform with new consequences from the Sleep Heart Health Study Research 
Group in which hormone-replacement treatment was related with an inferior possibility of 
sleep disordered breathing among post-menopausal women (Shahar, Redline et al. 2003). 
Obese PCOS patients are more likely to suffer from OSA compared to lean patients. The 
important morbidity and mortality, associated with this condition. PCOS patients should be 
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screened meticulously with regard to characteristics of daytime sleepiness, morning 
headaches, snoring, and other symptoms of OSA and directed for proper studies to verify 
this diagnosis. 
3. Subclinical atherosclerosis 
Even though the epidemiologic data on cardiovascular events are sparse in women with 
PCOS, the evaluation of cardiovascular structure and function is providing proof that PCOS 
and its related clinical phenotype clearly affects the arterial wall and/or myocardium. 
3.1 Carotid intima media thickness 
The CIMT has been displayed in numerous studies to predict cardiovascular events, with 
increasing CIMT correlated with an elevated age-adjusted cardiovascular risk (Bots, Dijk et 
al. 2002). Increased carotid intima media thickness (IMT), reminiscent of a raised risk for 
atherosclerosis, was displayed in a small group of PCOS patients over 40 years of age. 
However, there were no important discrepancies in the prevalence of carotid plaque 
amongst cases and controls (Guzick, Talbott et al. 1996). This result was independent of 
dyslipidemia but not plasma insulin levels and obesity. Nevertheless, Talbott et al. stated 
that CIMT measurements were only distinctive in older PCOS patients compared with 
controls, and after adjusting for coexistent cardiovascular risk factors PCOS was not a 
significant predictor of CIMT. This study additionally reported a substantially greater 
carotid plaque index in the PCOS subjects compared with controls. These results imply that 
in women with PCOS, subclinical atherosclerosis may not be obvious up to the time of the 
perimenopause (Talbott, Guzick et al. 2000). 
Recently, two researches to have displayed a significant difference in CIMT among young, 
normal weight PCOS patients compared with controls (Orio, Palomba et al. 2004; Vural, 
Caliskan et al. 2005). Vural et al. demonstrated that PCOS, BMI and a reduced sex hormone 
binding globulin were all independent predictors of CIMT (Vural, Caliskan et al. 2005). 
However, the report by Orio et al ., showed a strong association between CIMT and the free 
androgen index that suggests a contribution of hyperandrogenemia to evolvement of 
atherosclerosis in PCOS (Orio, Palomba et al. 2004). Contrarily, in a larger study raised 
CIMT was conversely correlated with plasma DHEAS and androstenedione concentrations, 
proposing a fascinating vasculoprotective influence of hyperandrogenemia in PCOS 
(Vryonidou, Papatheodorou et al. 2005). Meyer et al. also found a similar vasculoprotective 
effect of DHEAS in a study involving 80 obese women with PCOS, where higher DHEAS 
corresponded to notably lower CIMT (Meyer, McGrath et al. 2005). Whether the DHEAS has 
actually beneficial effects on atherogenesis in PCOS obscure and needs further studies to 
elucidate this issue. 
3.2 Coronary artery calcification 
Coronary artery calcification (CAC) demonstrates the grade of atherosclerosis and is early 
marker for clinical events. The electron beam computer tomography, has been employed to 
show raised arterial calcification in the coronary circulation in PCOS women compared with 
controls (Christian, Dumesic et al. 2003). Since adjusting for BMI, dyslipidemia remained a 
useful prognosticator of coronary calcification. The research of Mayo Clinic found a 3-fold 
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rise in CAC in non-diabetic PCOS cases than population controls (Christian, Dumesic et al. 
2003). Moreover, when these same participants were compared to obese control women, the 
participants with PCOS had 2-fold higher degrees of CAC. The intriguing prospective, case-
control research with over a nine year follow-up period in PCOS reported by Talbott et al. 
display an increased incidence of coronary and aortic arterial calcification (Talbott, Zborowski 
et al. 2004). Young obese PCOS patients have been shown to have a five times raised 
prevalence of subclinical CAD with the presence of momentous CAC as contrasted to age- and 
weight matched women (Shroff, Kerchner et al. 2007). The features of metabolic syndrome 
affect the grade of calcification, comprising central obesity, elevated blood pressure and 
dyslipidemia, and as a consequence insulin resistance. In that study, the degree of aortic 
calcification was also positively associated with plasma testosterone concentrations, 
questioning a presumed atheroprotective nature of hyperandrogenemia in PCOS. These 
reports, accompanied with angiographic statistics in women displayed a correlation among 
coronary artery disease and polycystic ovaries (Birdsall, Farquhar et al. 1997). 
3.3 Endothelial dysfunction 
Endothelial dysfunction is recognized to be an early characteristic in the progression of 
atherosclerosis, and the greater part of researches of macro- and micro-vascular endothelial 
function in women with PCOS has displayed significant peculiarities. The findings of the 
studies revealed that arterial dilatory function was a sign for the presence of endothelial 
dysfunction in distinct arterial beds in women with PCOS and was related to endothelial 
dysfunction among insulin resistance and less consistently to hyperandrogenemia. Related 
mechanisms almost certainly account for the effect of insulin resistance on the biology of 
NO in both conduit and resistance arteries in PCOS patients (Paradisi, Steinberg et al. 2001; 
Kelly, Speirs et al. 2002; Orio, Palomba et al. 2004). These studies collectively confirmed that 
increased arterial stiffness, myocardial and endothelial dysfunction showed solid 
pathophysiological proof for arterial atherosclerosis in women with PCOS. Many of these 
studies have shown a correlation between insulin resistance and cardiovascular 
abnormalities, and supported the hypothesis that insulin resistance remains at the vascular 
level in women with PCOS. However, still needs further proof for the associate with the 
clinical cardiovascular events. 
3.4 Ventricular function 
One of the early manifestations of diabetic cardiomyopathy is left ventricular (LV) diastolic 
dysfunction which has been recognized as a predictor for cardiovascular events in 
hypertensive patients (Schannwell, Schneppenheim et al. 2002; Schillaci, Pasqualini et al. 2002). 
Its etiology is multifactorial and refers to hypertension, coronary artery disease, insulin 
resistance, autonomic neuropathy, microangiopathy, dyslipidemia, endothelial dysfunction 
and oxidative stres (Brutsaert, Sys et al. 1993). The case control prospective studies that utilize 
echocardiographic methods demonsrated that women with PCOS were found to have a raised 
isovolumetric relaxation time (IVRT), an indicator of the early LV diastolic dysfunction, and 
lower ejection fraction in contrast to weight matched controls. In addition, an important clear 
connection among plasma insulin levels and IVRT was displayed in PCOS patients (Tiras, 
Yalcin et al. 1999). These results were consistent with another study which demonstrated an 
independent association between hyperinsulinemia and LV mass (Orio, Palomba et al. 2004). 
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The postulate that insulin resistance may contribute to myocardial dysfunction in PCOS has 
been supported with these studies’ findings. 
3.5 Aortic stiffness 
The peripheral circulation arterial stiffness is related to raised systolic blood pressure, pulse 
pressure and ventricular load, as well as to decreased diastolic perfusion of the coronary 
blood flow. Arterial stiffness may be assessed by two approaches. One is the 
ultrasonographic evaluation of carotid artery distensibility by measuring pulse wave 
velocity (PWV) and the other one analysis of the diastolic part of the radial waveform (Bots, 
Dijk et al. 2002). Arterial stiffness is increased in other diseases such as in renal failure it has 
been indicated to have prognostic value for cardiovascular events (London, Marchais et al. 
2004). Kelly et al. found increased pulse wave velocity of the brachial artery, but not of the 
aorta, in PCOS patients in a small case control study (Kelly, Speirs et al. 2002). Likewise, 
Lakhani et al. showed raised stiffness of both internal and external carotid arteries in 
women with both PCOS and PCO (ultrasonographic polycystic ovaries alone) compared 
with controls. Multivariate analysis implied independent influences of PCOS and PCO on 
arterial stiffness (Lakhani, Constantinovici et al. 2000). 
4. Cardiovascular events 
In spite of the fact that cardiovascular risk factors are more frequently found in PCOS 
patients, reliable proof for a raised prevalence of cardiovascular disease is lacking. The 
predicted relative risk of myocardial infarction was found 7,4 by the calculated risk factor 
profile in a small group of women (n = 33) with histopathological verification of polycystic 
ovaries (PCO) compared with aged-matched controls (Dahlgren, Janson et al. 1992).  
A subsequent study that included 142 women undergoing coronary angiography revealed 
that polycystic ovaries were independently correlated with the presence of an extent of 
coronary atherosclerosis determined during catheterization. The examination of pelvic 
ultrasonography imaging showed that forty two percent of these women had polycystic 
ovaries. Moreover, these patients had more extensive coronary artery disease than the group 
without polycystic ovaries, established on a number of segments by more than 50% stenosis 
(Fogel, Malhotra et al. 2001). 
Nevertheless, a larger retrospective cohort found that PCOS patients (n = 345) diagnosed 
primarily with ovarian morphology, had further cardiovascular risk factors, comprising 
obesity, diabetes, hypertension and hyperlipidemia. Their mortality and morbidity from 
coronary heart disease didn't show a disparity from age-matched controls (n = 1060) (Wild, 
Pierpoint et al. 2000). This remarkable result could be explained with the ascertainment bias, 
to application of a non-standard description of PCOS, or perhaps to a cardiovascular 
defensive impact of hyperandrogenemia. Even though, after adjusting for BMI, the odd's 
ratios for developing diabetes and cerebrovascular disease in this analysis were raised 
considerably at 2.3 and 2.8, respectively. 
The Women’s Ischemia Syndrome Evaluation (WISE) is the most important study that 
evaluated both cardiovascular risk and consequences in women with PCOS. WISE is a 
multicenter research that intends to ameliorate diagnostic testing for ischemic heart disease 
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in women and to study pathophysiology and prognosis in women with symptoms and 
proof of myocardial ischemia in the absence or presence of obstructive coronary artery 
disease (CAD). The researchers included 390 postmenopausal women and diagnosed PCOS 
with the rise in blood serum androgen concentrations integrated with a premenopausal 
history of irregular menses (n =104). Notably, the prevalence (27%) of PCOS was 
considerably higher than the population anticipation (5%–8%). However, women with 
ischemia may represent a refined pool for women with PCOS. Clinically most significant 
consequence is the cumulative 5-year cardiovascular event-free survival was 78.9% for 104 
women with PCOS and 88.7% for 286 women without PCOS (Shaw, Bairey Merz et al. 2008).  
Two more studies provided further support to the link between PCOS and CVD. One of them 
is a cross-sectional study, which included 713 postmenopausal women (mean age, 73.8 yr) and 
found in nondiabetic women with intact ovaries, a step-by-step categorized association 
between CVD and quantities of features of assumed PCOS, as described by premenopausal 
menstrual irregularity, hirsutism, or present biochemical hyperandrogenism (Krentz, von 
Muhlen et al. 2007). The other case-control study recruited 414 postmenopausal women (mean 
age, 60.4 yr), used premenopausal menstrual irregularity as a putative sign of PCOS, and 
found an increased odd's ratio for coronary vascular disorder (Azevedo, Duarte et al. 2006). 
Since the majority of studies centered on surrogate results and there are weak at detecting true 
discrepancies in these consequences, we need extended-course of data to evaluate real risk. 
5. Management of CVD risk factors 
The PCOS treatment aims at amelioration of ovarian function, involving regulating and 
averting anovulatory uterine hemorrhagia, diminishing obesity, controlling cardiovascular 
risk factors such as insulin resistance, diabetes, hypertension, hyperlipidemia. Nevertheless, 
there is no better treatment alternative distinct from lifestyle modification. Numerous 
researches indicated that improving insulin sensitivity with lifestyle modifications or 
pharmacological treatment can diminish circulating androgen levels, and increase 
spontaneous ovulation and pregnancy. 
5.1 Lifestyle modification 
The most valuable approaches for improving insulin sensitivity in overweight, obese PCOS 
patients are diet, weight reduction, and physical activity. Obesity has changed into an 
epidemic in most parts of the world and has a marked on reproductive and metabolic 
peculiarities in women with PCOS. Regrettably there are no optimized medical therapies at 
this point that causes a permanent weight loss. Moreover, it was reported that 90–95% of 
subjects who achieved a weight loss will generally relapse (Rosenbaum, Leibel et al. 1997). 
The efficacious surgical alternative for the morbidly obese PCOS patients may be a bariatric 
surgery. However, there has been a few reports of this intervention in this special group. 
The lifestyle modification for overweight/ obese patients, comprising diet, exercise, 
termination of smoking, and behavioral modification (Norman, Davies et al. 2002), may 
have beneficial effects to decrease CVD risk (De Backer, Ambrosioni et al. 2003). The 
researches revealed that short-period weight-loss intervention in PCOS patients lowers 
abdominal fat (Andersen, Seljeflot et al. 1995; Holte, Bergh et al. 1995), lessens androgen 
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levels (Holte, Bergh et al. 1995), IR and in addition ameliorates dyslipidemia, depression, 
and quality of life, even though long-term weight loss is improbable (Andersen, Seljeflot et 
al. 1995; Thomson, Buckley et al. 2010). 
Numerous studies in PCOS patients have demonstrated, that weight reduction can 
ameliorate the main characteristics of the endocrine syndrome of PCOS. Weight reduction 
decrease circulating androgen levels and restart the menstrual cycle (Guzick, Wing et al. 
1994; Okajima, Koyanagi et al. 1994; Clark, Ledger et al. 1995).These alterations can be 
obtained with a weight loss as small as 5% of the initial weight (Franks, Kiddy et al. 1991; 
Kiddy, Hamilton-Fairley et al. 1992). Additional advantages that have been reported to have 
lowered circulating insulin levels (Kiddy, Hamilton-Fairley et al. 1989; Kiddy, Hamilton-
Fairley et al. 1992). The reduction of free testosterone concentrations, subsequent weight loss 
mostly mediated through increases by SHBG (Franks, Kiddy et al. 1991; Kiddy, Hamilton-
Fairley et al. 1992). 
The hypocaloric, low saturated fat, increased mono- and polyunsaturated fat nutrition is 
advocated, simultaneously with at least 30 min of intermediate-strength physical activity 
every day to maintain weight. Together both decrease BMI and ameliorate IR and 
cardiopulmonary function in overweight/obese PCOS patients (Vigorito, Giallauria et al. 
2007) and performed greater decreases in fat mass in PCOS women (Bruner, Chad et al. 
2006). Altering a dietary macronutrient constitution does not offer a benefit for weight loss 
over prevalent dietetic approaches solely (Moran, Pasquali et al. 2009). 
However, the majority of PCOS patients difficult to achieve desirable weight loss, despite a 
caloric reduction and modification to healthier diets and physical activity. It may be even 
harder for these subjects to maintain weight loss, especially whether they are insulin 
resistant. As well as 10-30% of women with PCOS are lean, weight loss is not a choice for 
their management. 
5.2 Insulin sensitizers 
Medications developed to treat type 2 diabetes that have insulin sensitizing properties (ie, 
metformin and thiazolidinediones) have been utilized to treat PCOS, because both diseases 
are thought to be developed based on impaired insulin action. This class of medication 
enhance insulin sensitivity and transform impaired to normal glucose tolerance in non-
diabetic women with PCOS. These drugs, additionally improve metabolic predictors of 
cardiovascular risk in PCOS patients, comprising serum triglycerides, PAI-I, and lower 
blood pressure (Diamanti-Kandarakis, Kouli et al. 1998; Moghetti, Castello et al. 2000). The 
data provided from the UKPDS, a research of diabetic men and women, showed that there 
may be lesser cardiovascular events in insulin-resistant individuals treated with insulin-
sensitizing drugs (1998). 
5.2.1 Metformin 
Metformin is one of the most frequently prescribed drugs to treat PCOS. Metformin has 
constantly shown an insulin lowering effect, and that may be its prime mechanism of action. 
Metformin was certified for the usage of type 2 diabetes by the FDA in 1994, although has 
been used clinically for approximately to 20 years formerly in other parts of the world 
(Coetzee and Jackson 1979). 
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Study results regarding the effects of metformin on primary prevention of CVD are not 
coherent (Moghetti, Castello et al. 2000; Diamanti-Kandarakis, Alexandraki et al. 2005; Rautio, 
Tapanainen et al. 2005). Metformin has a little influence on body weight (less than 2–3% of 
BMI) (Moghetti, Castello et al. 2000; Rautio, Tapanainen et al. 2005; Nieuwenhuis-Ruifrok, 
Kuchenbecker et al. 2009) and may ameliorate atherogenic dyslipidemia, raising HDL-C and 
lowering triglycerides (Rautio, Tapanainen et al. 2005; Trolle, Flyvbjerg et al. 2007). 
Nevertheless, no alterations in HDL-C or triglycerides were seen in some studies 
(Banaszewska, Pawelczyk et al. 2009). Metformin cannot improve LDL-C or non-HDL-C 
(Rautio, Tapanainen et al. 2005; Trolle, Flyvbjerg et al. 2007; Banaszewska, Pawelczyk et al. 
2009). Furthermore, several studies with metformin have shown that, it lessens of circulating 
C-reactive protein, PAI-1 (Velazquez, Acosta et al. 1997; Morin-Papunen, Rautio et al. 2003) 
and may ameliorate premature atherosclerosis, decrease carotid IMT and enhance endothelial 
function (Diamanti-Kandarakis, Alexandraki et al. 2005; Agarwal, Rice et al. 2010).  
The research of Sharma et al. investigated the efficacy of metformin in averting progression 
to type 2 diabetes, particularly in PCOS patients. During 43.3 months of treatment with 
metformin, 5% (N.=2) of the 39 patients with normal glucose tolerance at baseline 
transformed to impaired glucose tolerance, bearing an annual conversion rate of 1.4%. The 
published article's stated a 16-19% annual conversion rate for PCOS women, therefore, 
rendering a 11-fold decrease in the annual conversion to impaired glucose tolerance in this 
metformin given PCOS women. Moreover, none of the fifty PCOS women developed 
diabetes throughout the study period (Sharma, Wickham et al. 2007). 
5.2.2 Thiazolidinediones 
Thiazolidinediones (TZDs) have been proposed as a treatment option for many of the 
metabolic aspects of PCOS. These drugs act by increasing insulin stimulated glucose uptake, 
principally in adipose and skeletal muscle tissues. The activation of Ǆ-peroxisome proliferation 
activator receptors (PPAR-Ǆ) activates the genes that encode insulin. Troglitazone was the first 
to be used in this class. Troglitazone treatment improved endothelial function in obese PCOS 
patients when compared to age and weight matched controls (Paradisi, Steinberg et al. 2003) . 
The same result was obtained with rosiglitazone (Tarkun, Cetinarslan et al. 2005) and 
pioglitazone (Romualdi, Guido et al. 2003). Troglitazone additionally lowered circulating 
insulin levels, improved hirsutism, and increased the ovulation rates of PCOS patients 
(Paradisi, Steinberg et al. 2003)(Dunaif, Scott et al. 1996). A study examined the effects of 
metformin, rosiglitazone, and a combination of these drugs in non-obese PCOS patients with 
no clinical or biochemical proof of insulin resistance. Together with other findings, measures 
of insulin sensitivity was ameliorated meaningfully with metformin and combination therapy, 
but not with rosiglitazone solely (Baillargeon, Jakubowicz et al. 2004). 
Troglitazone and rosiglitazone, at present, are not available due to liver toxicity and 
cardiovascular side effects respectively. Pioglitazone is the only available molecule in this 
class and to date did not have the hepatic side effects of their predecessors. A new study 
closely assessed cardiovascular risk factors in women with PCOS randomized to 
pioglitazone or placebo for 16 weeks (Glintborg, Hojlund et al. 2008). Enhancement of 
insulin sensitivity determined with clamp technique, however a serum marker of 
atherosclerosis sCD36 and hs-CRP significantly diminished. Insignificant alterations were 
measured in body weight or body composition in the treatment patients, which was 
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unexpected, given the tendency to weight gain with thiazolidinedione remedies. Another 
recent analysis randomized 60 women with PCOS for 24 weeks to exenatide (a glucagon-like 
peptide-1 [GLP-1] analogue in the incretin class of drugs), metformin, or a combination of 
both (Elkind-Hirsch, Marrioneaux et al. 2008). The research revealed greater weight loss 
with exenatide than with metformin and found an additive effect of both. Even though no 
serious side effects (ie, pancreatitis with exenatide) were noted althought the knowledge 
with incretins in women with PCOS is very limited. 
5.3 Cholesterol lowering drugs 
The HMG-CoA reductase inhibitors are a class of cholesterol- lowering agents, also 
recognized as statins, are blocking the rate limiting step of cholesterol synthesis. Restriction 
of mevalonate production may furthermore cause diminished maturation of insulin 
receptors, inhibition of steroidogenesis (via restricting the substrate cholesterol), and change 
of signal transduction pathways that mediate cellular proliferation (Kodaman and Duleba 
2008). They are thought to have a favorable influence on cardiovascular risk independent of 
their lipid-lowering effect as well, expectedly by pleiotropic activity on systemic 
inflammation and oxidative stress, the mechanism of which is still to be determined. Stress 
and inflammation are also thought to play a role in the progression of ovarian theca cell 
hyperplasia, lead to anovulation and hyperandrogenism in PCOS. 
Even though several lipid-lowering medications have been tried (Rizzo, Berneis et al. 2008; 
Rosenzweig, Ferrannini et al. 2008), only statins have been adequately studied in women 
with PCOS and have efficiently lowered LDL-C levels (Banaszewska, Pawelczyk et al. 2009; 
Sathyapalan, Kilpatrick et al. 2009) . Several studies found that, statins decrease IR and 
inflammation, reduce serum total and free testosterone concentrations, and ameliorate 
endothelial dysfunction in PCOS patients (Duleba, Banaszewska et al. 2006; Banaszewska, 
Pawelczyk et al. 2009; Sathyapalan, Kilpatrick et al. 2009). Nevertheless, their usage in 
gestation is contraindicated, and contraception is needed. 
Patients with serious dyslipidemia that is not adequately corrected by lifestyle modification 
and statins may need double pharmacotherapy. It has been found that the addition of 
metformin does not ameliorate lipid levels furthermore (Banaszewska, Pawelczyk et al. 
2009). Statins combined with a fibrate may be required when hypertriglyceridemia and low 
HDL levels coexist. Fenofibrate is favored because of less drug interactions and the 
diminished possibility of myopathy (Zambon and Cusi 2007; Rosenzweig, Ferrannini et al. 
2008). Nicotinic acid causes a beneficial effect on lipoproteins however needs cautious 
monitoring for deterioration of glycemic control (Rosenzweig, Ferrannini et al. 2008). 
5.4 Hypertension theraphy 
Antihypertensive drug medication is recommended for blood pressure of more than 140 
mmHg systolic or 90 mmHg diastolic. Since milder elevation of BP (or prehypertension), 
increase CVD risk, diminishing BP to 120/80 mm Hg is desirable for longtime CVD 
protection (Rosenzweig, Ferrannini et al. 2008). Most of the researchers recommend merging 
pharmacotherapy accompanied by lifestyle modification for incessant hypertension in PCOS 
patients. Even though some investigators favor angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers over diuretics and beta-blockers, utilitization of 
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angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics and beta-
blockers is contraindicated in pregnancy and requires contraception. 
5.5 Antiobesity medications 
Phenteramine, sibutramine, and orlistat are FDA-approved weight loss medicines. A 
number of researches have found that sibutramine combined with a hypocaloric diet 
enhances weight loss, improves IR, and hypertriglyceridemia, decrease serum free 
testosterone concentrations, to a greater extent than hypocaloric diet alone. However, this 
drug may raise diastolic BP and heart rate and is not approved in the course of gestation. 
Orlistat causes a smaller degree of weight loss. Since the clinical experience with these 
agents is limited in PCOS and unexpected side effects may happen, authorities do not 
advocate the utilitization of weight loss medicines in women with PCOS. 
6. Conclusion and future aspects 
Although the epidemiologic data is uncertain, current study results strongly support a 
correlation between PCOS and cardiovascular risk factors, which are represented in Figure 1. 
Discrepancies among some of the reports reviewed in this chapter, may be due to small 
sample sizes, bias in case-control designs and the non-standard delineations of PCOS criteria.  
Data accumulated to date, indicate that insulin resistance, and obesity may be responsible for 
early ventricular functional abnormalities, arterial stiffness, endothelial dysfunction and both 
carotid and coronary atherosclerosis. These abnormalities may be detrimental consequences of 
insulin resistance per se, such as dyslipoproteinemia, hypertension, low grade inflammation, 
raised oxidative stress, changed hemostasis and coagulation system alterations. The 
diminished synthesis of nitric oxide (NO) and excess production of peroxinitrite are 
apparently principal factors to initiate endothelial dysfunction and atherothrombosis. 
The function of hyperandrogenemia in subscribing to the cardiovascular abnormalities 
surveyed remains obscure and debatable. Most researches detected androgens as a 
cardiovascular risk in women with PCOS. Even though the minority of reports examined 
indicated an independent correlation of androgens with impaired cardiovascular structure or 
function. This additionally strengthens the thought that cardiovascular risk in PCOS resides to 
insulin resistance rather than hyperandrogenemia. Furthermore, some studies showed that in 
PCOS patients, androgens, particularly DHEAS, have been a negative association with CIMT. 
Weight loss is realizable with lifestyle alterations, bariatric surgery, and pharmaceutical 
treatment, involving antiobesity and antidiabetic medications. Insulin sensitizers and 
statins, particularly in combination with hormonal remedies such as OCPs, oral 
contraceptives seem to have beneficial properties. Nonetheless, greater and longer trials are 
required previously to elucidate, which is the best treatment to impede cardiovascular 
events in women with PCOS can be advocated. 
The postulation for the development of cardiovascular disease in PCOS founded on the 
studies surveyed and permitting the illustration in Figure 1.It summarizes possible pathways 
throughout the cardiovascular risk factors to CVD. However, the presence of these 
cardiovascular risk factors in women with PCOS, at this time sufficient prospective results that 
supporting the actual prevalence of cardiovascular events in PCOS patiens are lacking. 
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Fig. 1. Postulation for the pathogenesis of cardiovascular disease in PCOS. This figure 
outlines possible pathways which cardiovascular risk factors associated with PCOS may 
render into manifest cardiovascular disease.  
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Definitive prospective data to support a rise in adverse cardiovascular events in women 
with PCOS is non-existent. However, the most recent studies have firmed up the connection 
among women with PCOS and CVD events, even though they tend to present in menopause 
and not in reproductive-age women. Former prediction models have appraised a 
proportional risk of myocardial infarction of 7.4 PCOS patients. Nevertheless, a large 
retrospective report of PCOS women showed elevated ratios of diabetes and 
cerebrovascular disease but not cardiovascular disease, proposing that the earlier estimate 
of cardiovascular risk may have been extreme. Consequently, that researches perform 
hereafter have to analyses cardiovascular health results and endeavour to clarify those 
subgroups that are sharper risk for cardiovascular disease in women with PCOS. 
From a clinical aspect, the current statistics imply that management should focus on the 
designation and treatment of peculiar cardiovascular risk factors recognized to occur more 
frequently PCOS patients. In particular, lifestyle modification, the avoidance of weight gain 
and obesity, and the long-term surveillance for evolvement of type 2 diabetes should be 
accented. After menopause conventional cardiovascular risk accelerates in women, have to 
be evaluated with precisely mentioning to PCOS. The consequences of interferences such as 
exogenous oestrogens and anti-androgen treatment on cardiovascular risk in PCOS also 
required to be investigated further. The high prevalence of this disease in reproductive age 
women, and the possible correlation with cardiovascular disease, cause future examinations 
in this issue a priority importance from both a public health and clinical aspect. 
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